Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Novo doubles down on next-gen weight loss therapy despite early setback
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Healio5h
Top in endocrinology: Metformin plus Mediterranean diet; lean mass loss with GLP-1s
A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
'Good' cholesterol might not be so good for glaucoma
The cholesterol that's good for your heart health might be bad for your eye health and vice versa, a new study says.
Hosted on MSN7h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Wellness, GLP-1 weight loss drugs and the Super Bowl—behind the emerging trend
Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.
Hosted on MSN9h
Looking To Come Off GLP-1 Injectables? Try Calocurb, a Natural Appetite Suppressant, Instead!
Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.
Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA
The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.